Skip to main content
Equibles
PLUR logo

PLUR · Pluri Inc. · Metrics

Track PLUR — free

Use PLUR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLUR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.08 -0.06 (-5.26%)
Rebalance outlook locked
Going-concern doubt — flagged Sep 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“According to management estimates, we have sufficient resources to meet our operating obligations for a period of less than three months from the issuance date of our consolidated financial statements, which was September 10, 2026. These conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-K filed Sep 10, 2026
Market Cap
$15.49M
Shares
12.34M

PLUR metrics

62 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.14
Market cap
$15.49M

Price action

20 metrics
Price change (1W)
-7.5%
Price change (30D)
-26.6%
Price change (3M)
-47.8%
Price change (6M)
-63.6%
Price change (YTD)
-60.7%
Price change (1Y)
-76.0%
Trailing year
Price change (5Y)
—
52-week high
$4.90
52-week low
$1.17
Change from 52-week high
-76.0%
Change from 52-week low
+0.0%
Annualized volatility
71.9%
Annualized volatility (3M)
77.0%
Beta
0.7
RSI (14D)
32.8
Price vs SMA 50
-27.7%
Price vs SMA 200
-57.2%
Avg volume (3M)
29,949
Relative volume
0.4
Average dollar volume
$53,087

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
12.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
15.2×
reciprocal yield 6.6%
P / book
—
FCF yield
-130.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-153.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
44.6%
Operating margin
-2,454.5%
Trailing 12 months
Net margin
-2,344.6%
Gross profit (TTM)
$453,000
Operating profit (TTM)
−$24.94M
Net income (TTM)
−$23.82M
Trailing 12 months
Diluted EPS (TTM)
$-2.44
FCF margin
-1,990.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.13

Growth

11 metrics
Revenue growth YoY
-15.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.02M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+53.2%
Year over year · more shares
Revenue CAGR (3Y)
+52.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-95.8%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$24.43M
Free cash flow (TTM)
−$20.22M
Quick ratio
0.3
Interest coverage
-26.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.53M
Total assets
$24.88M
Total debt
$13,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.59M
Capital expenditures (TTM)
$633,000
R&D (TTM)
$15.09M
SG&A (TTM)
—
Stock compensation (TTM)
$3.73M
R&D / revenue
1,485.4%
Stock compensation / revenue
366.7%

Ownership (13F)

3 metrics
13F filers
16
13F filer change QoQ
+2
Institutional ownership
0.2%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1158780 CUSIP 72942G203 Visit website Investor relations